Stocktoria
Evommune, Inc. EVMN
Evommune, Inc. (EVMN) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $13.0M at a -529.8% net margin.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.603 |
| Retained earnings / assets | -0.983 |
| EBIT / assets | -0.36 |
| Equity / liabilities | 10.607 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EVMN | Evommune, Inc. | 2/9 | 9.47 | — | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 3/9 | -0.37 | — | +29.8% |
| PYXS | Pyxis Oncology, Inc. | 2/9 | -16.86 | — | -14.2% |
| PRLD | Prelude Therapeutics Inc | 3/9 | -17.29 | — | — |
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
| IRD | Opus Genetics, Inc. | 3/9 | -11.42 | — | +29.1% |
| JAGX | Jaguar Health, Inc. | 2/9 | — | — | -1.5% |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
FAQ
Is EVMN financially healthy?
Evommune, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does EVMN pay a dividend?
No, Evommune, Inc. does not currently pay a dividend.
How profitable is EVMN?
In FY2025, Evommune, Inc. had a net margin of -529.8% and a return on equity of -33.5%.
What is the analyst price target for EVMN?
The average Wall-Street price target for Evommune, Inc. is $41.25, about 192.1% above the recent price, from 8 analysts (consensus: strong buy).
Is EVMN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Evommune, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.